Formulation Studies of an Adsorbed Conjugate Vaccine - How a thorough formulation study ensured the development of a stable and effective vaccine. - BioPharm International


Formulation Studies of an Adsorbed Conjugate Vaccine
How a thorough formulation study ensured the development of a stable and effective vaccine.

BioPharm International Supplements


The Phase 1 formulation consisted of 20 μg/mL GCMP–TT (μg refers to GCMP) in 150 mM NaCl (saline), 0.01 % thimerosal and 1 mg/mL aluminum (added as aluminum hydroxide), and filled in single-dose vials with a deliverable dose of 0.5 mL. The 3 mL vial was Type 1 Flint glass and the closure was 13 mm chlorobutyl rubber stoppers. After four years of storage at 5 C, the pH of the vaccine rose from 5.5 to 7.3. The slow rise in pH was caused by gradual leaching of alkaline from the glass vials.

Phosphate buffered saline (PBS, 10 mM sodium phosphate and 150 mM NaCl, pH 7.4) was chosen for the Phase 2–3 clinical formulation because of pH stability concerns in the unbuffered vaccine.

The adsorption kinetics were studied at small scale and GCMP ELISA (method A) was used to measure percent adsorption. Adsorption of GCMP–TT to aluminum hydroxide gel in saline reached completion instantaneously (>99.9% adsorbed). Adsorption in PBS went slowly and in an hour only 98% was adsorbed. For clinical production, we formulated in PBS for one hour and used a tentative specification of ≥90% for percent adsorption. The formulated vaccine was filled into 1-mL syringes with a 0.5-mL deliverable dose. The syringe barrels were silicon lubricated European and US Pharmacopeia type 1 borosilicate glass (Becton Dickinson). The closures were siliconized bromobutyl plunger stoppers. Medical grade DC 360 silicone helped stopper placement and movement and was consistent with US standards. Tip caps (chlorobutyl natural rubber blend) maintained sterility of the closure. Thimerosal preservative was not necessary for single-dose fills and was eliminated. The formulation consisted of 20 μg/mL GCMP–TT and 1 mg/mL aluminum in PBS.

Two lots (49801 and 49802) were produced for Phase 2–3 trials and placed on stability studies. The stability indicating methods included percent adsorption, pH, potency, sterility, general safety, and appearance.

After completing formulation, the percent adsorption samples were taken from the formulated bulk and determined to be 97% and 98% (method A) for lots 49801 and 49802, respectively. Both lots passed specification.

Table 1. Desorption of conjugate vaccine from the aluminum hydroxide adjuvant in PBS
Before the start of clinical trials, percent adsorption dropped for both lots as determined by GCMP ELISA. Because of the decrease in percent adsorption, the supernatant contained detectable amounts of GCMP and protein that allowed us to confirm the percent adsorption by chemical assays measuring sialic acid and protein, respectively (Table 1).2,3

blog comments powered by Disqus



First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here